| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 95.11 | 9045 |
| Intrinsic value (DCF) | 4.46 | 329 |
| Graham-Dodd Method | n/a | |
| Graham Formula | n/a |
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.